Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | PROSPER: Enzalutamide vs. placebo for nmCRPC

Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium, explains the findings of the PROSPER (NCT02003924) trial which investigated the safety and efficacy of enzalutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.